TRT — Side Effects and Therapy Monitoring
Erythrocytosis, fertility impact, PSA screening, and the cardiovascular risk question — what testosterone replacement therapy safety actually involves and how it's monitored.
Number of studies
2
Safety
Requires caution
Time to effects
Not applicable — monitoring is an ongoing process that continues throughout the entire course of therapy.
Who it's for
Table of contents
TL;DR
Erythrocytosis, fertility impact, PSA screening, and the cardiovascular risk question — what testosterone replacement therapy safety actually involves and how it's monitored.
- →Early detection of erythrocytosis allows dose or injection frequency to be adjusted before risk actually rises
- →Regular PSA monitoring enables prompt detection of concerning prostate changes
- →Awareness of the fertility impact allows therapy or alternatives to be planned ahead of time, not after the fact
| Intervention type | Safety and monitoring protocol for hormone therapy |
|---|---|
| Level of evidence | Strong — large RCT (TRAVERSE) and clinical guidelines |
| Target group | All patients undergoing TRT |
| Time to effects | Not applicable — ongoing monitoring |
| Preparation needed | Regular blood work (CBC, PSA, lipid panel) every 3–12 months |
| Status | Standard of care during therapy, not an optional add-on |
Understand
Overview
TRT, despite a well-characterized safety profile, requires regular medical oversight — it isn't a "set it and forget it" therapy. The most closely monitored and best-documented side effect is erythrocytosis (an excessive rise in red blood cell count and hematocrit), which theoretically raises the risk of thrombosis.
The second important area is fertility — externally administered testosterone suppresses LH and FSH secretion through negative feedback, reducing sperm production, sometimes down to azoospermia. The effect is usually reversible after stopping therapy, but reversal can take months. The third, historically controversial topic is cardiovascular risk — the large, modern TRAVERSE trial from 2023 showed that TRT did not increase the risk of major cardiovascular events in men with hypogonadism and risk factors, though it still calls for individual assessment.
Men planning fatherhood in the near future should discuss alternatives or deferring TRT with a doctor — this is one of the few situations where therapy is knowingly withheld despite confirmed hypogonadism. For most other patients, the key to safety isn't avoiding TRT but rather regular, planned monitoring.
Mechanism of action
Testosterone stimulates erythropoiesis — it increases erythropoietin production in the kidneys and improves iron utilization, which leads to a rise in red blood cell count and hematocrit. This is the best-understood, dose-dependent mechanism behind TRT side effects, which is why a complete blood count with hematocrit is the core monitoring test.
In parallel, exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis through negative feedback, lowering LH and FSH, and consequently the intratesticular testosterone concentration needed for normal spermatogenesis. A separate mechanism is the potential stimulation of prostate tissue growth — according to current knowledge, testosterone does not initiate prostate cancer de novo, but it may accelerate the growth of an existing, previously undetected tumor, which is why PSA monitoring before and during therapy is standard practice.
Stimulation of erythropoiesis
Testosterone increases erythropoietin production and iron absorption, raising red blood cell count.
Suppression of the hypothalamic-pituitary-gonadal axis
Negative feedback lowers LH and FSH, limiting natural sperm production.
Potential stimulation of prostate tissue
Testosterone may accelerate the growth of an existing, subclinical prostate cancer, but according to current knowledge does not initiate it de novo.
Cardiovascular effects
Previously a controversial area, now largely clarified by the large, randomized TRAVERSE trial.
Evidence: strong — based on 2 studies in this database.
Benefits
Common myths
MythTRT always increases the risk of heart attack.
FactThe large TRAVERSE trial (2023) found no increased risk of major cardiovascular events with properly supervised therapy in men with risk factors.
MythTRT's effect on fertility is permanent.
FactReduced sperm production is usually reversible after stopping therapy, though returning to baseline fertility can take many months.
Practice
Frequently asked questions
Usually 3 months after starting therapy, then every 6–12 months once results are stable — the treating physician sets the exact schedule.
Usually not — the effect is reversible in most cases after stopping therapy, though fertility can take from several months to over a year to return.
Current data don't indicate that TRT causes prostate cancer from scratch, but it may accelerate the growth of an existing, previously undetected tumor — which is why PSA monitoring before and during therapy is standard.
Dosage & timing
Typical dose
Not applicable — this entry describes a safety protocol, not therapy dosing
Form
Monitoring: complete blood count with hematocrit every 3–6 months in the first year, PSA and digital rectal exam before starting and periodically thereafter, lipid panel once a year
Monitoring frequency is often adjusted individually by the treating physician.
Best times to take it
- The first check-up is usually 3 months after starting therapy, then every 6–12 months once results are stable
Safety
Side effects & contraindications
Possible side effects
Erythrocytosis (elevated hematocrit) — the most common finding requiring monitoring
Reduced fertility, in some cases down to azoospermia
Acne and oily skin
Fluid retention, edema
Rarely: gynecomastia due to conversion to estrogen
Contraindications
Active or recently treated prostate cancer
Uncontrolled erythrocytosis (hematocrit above roughly 54% without explanation)
Planning to conceive a child in the near term without prior consultation
Severe, untreated sleep apnea — therapy may worsen it
Interactions
Anticoagulants — require closer monitoring when erythrocytosis is present simultaneously
Insulin and antidiabetic medications — testosterone may improve insulin sensitivity, requiring dose adjustment
Is it worth taking?
Who it's for
- All patients starting or continuing TRT
- Men planning fatherhood, before deciding on therapy
Not for
- Active or recently treated prostate cancer
- Uncontrolled erythrocytosis (hematocrit above roughly 54% without explanation)
- Planning to conceive a child in the near term without prior consultation
- Severe, untreated sleep apnea — therapy may worsen it
Evidence
Worth knowing
Erythrocytosis is the most common reason for adjusting TRT dose or frequency in clinical practice.
The TRAVERSE trial (2023) enrolled more than 5,000 men and is by far the largest RCT to date assessing TRT's cardiovascular safety.
Studies
In a large, randomized trial in men with hypogonadism and elevated cardiovascular risk, testosterone therapy did not increase the incidence of major cardiovascular events compared with placebo.
Lincoff AM et al. (TRAVERSE trial), New England Journal of Medicine, 2023
Cardiovascular Safety of Testosterone-Replacement Therapy in Men (TRAVERSE)
Strong evidenceLincoff AM, Bhasin S, Flevaris P, et al. · New England Journal of Medicine · 2023
A large randomized trial (n>5000) assessing the cardiovascular safety of TRT in men with hypogonadism and risk factors — found no increased risk of major cardiovascular events.
View studyTestosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
Strong evidenceBhasin S, Brito JP, Cunningham GR, et al. · Journal of Clinical Endocrinology & Metabolism · 2018
Clinical guidelines defining the recommended monitoring schedule for testosterone therapy safety.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr reviews content on hormones, metabolic health and supplement pharmacology.
131 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.
50 publications on this site
Related entries
4.7Testosterone
The primary anabolic hormone — its natural level depends heavily on sleep, resistance training, body composition and fat mass.
4.4TRT — Administration Forms: Injections, Gels, and Patches
Injections, transdermal gels, and patches — the three main forms of testosterone replacement therapy differ in blood-concentration profile, ease of use, and the risk of transferring the hormone to other people.
4.6Hypogonadism — Diagnosis and Criteria for TRT Eligibility
Not every low testosterone result means hypogonadism requiring treatment. We explain which laboratory and symptomatic criteria must be met before TRT becomes a justified option.
4.7TRT (Testosterone Replacement Therapy) — What Is It and Who Is It For?
TRT isn't a supplement for fatigue — it's pharmacological treatment for a confirmed testosterone deficiency, with a real but limited list of benefits and an equally real list of people who simply don't qualify for it.
4.7What Tests Are Needed Before TRT? The Complete Pre-Treatment Testing List
Before a physician can qualify a patient for testosterone therapy, a far broader panel of tests is needed than testosterone level alone. The full list of blood tests, symptom questionnaires, and criteria that determine whether TRT is safe and appropriate.
4.7How Often to Test Testosterone on TRT? Monitoring Schedule and Checkups
Starting testosterone therapy isn't the end of diagnostics — it's the start of a new, recurring rhythm of checkups. We explain which tests happen at month 3, which at year one, and which need repeating for as long as therapy continues — and how the schedule differs between injectable and gel forms.
4.7TRT and Your Heart — Does Testosterone Therapy Raise Heart Attack Risk?
For a decade, testosterone therapy operated under the shadow of an FDA warning about heart attack risk. The large randomized TRAVERSE trial from 2023 finally gave a clear answer — though not as simple as the headlines suggested. We walk through the whole story, from controversial observational studies to where the evidence stands today.
4.7Testosterone Enanthate — How It Works and What to Expect During TRT
One of the two most widely used injectable testosterone esters in TRT worldwide, alongside cypionate. We explain its characteristic peak-then-trough profile, typical injection schedules, and what a patient can realistically expect across a dosing cycle.
Related articles
PoradnikiTRT or Lifestyle Change? What Actually Raises Testosterone Before You Consider Therapy
Before considering testosterone replacement therapy, it's worth checking how much sleep, training, and fat loss can realistically achieve — and when these interventions genuinely aren't enough.
July 29, 2026
PoradnikiTRT Side Effects: What Should You Actually Worry About?
Internet forums warn of prostate cancer and heart attacks, while for most patients the real everyday issue is thicker blood and acne. We've sorted TRT's side effects by actual risk — not by what sounds the most terrifying.
August 15, 2026
PoradnikiDoes TRT Cause Hair Loss, Acne, and Gynecomastia? Fact vs. Myth
Hair loss, acne, and 'man boobs' are the three most-Googled worries before starting TRT — but none of them is a guaranteed consequence of therapy. We check what physiology and the research actually say about mechanism, dose, and individual susceptibility.
August 15, 2026
PoradnikiThe Most Common TRT Mistakes — 15 Things That Can Undermine Your Therapy's Results
A wrap-up of our entire testosterone therapy series: fifteen common, real mistakes — from diagnostics to discontinuation — that can turn a well-designed TRT protocol into a source of disappointment or genuine health risk.
August 15, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.
